About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
IP: Rafael Simó Canonge Collaborators: - Funding agency: Fundació Institut de Recerca HUVH Funding: 160000 Reference: SIMO/BOOST/2024 Duration: 15/11/2024 - 14/11/2028
IP: Carles Zafon Llopis Collaborators: Jordi Temprana Salvador, Carmela Iglesias i Felip Funding agency: Fundación Sdad Española Endocrinologia y Nutrición Funding: 10000 Reference: SEEN/PROJECTE/ZAFON/2024 Duration: 01/01/2025 - 01/01/2026
IP: Albert Lecube Torelló Collaborators: Marta Comas Martinez, Enzamaría Fidilio Meli Funding agency: Instituto de Salud Carlos III Funding: 117370 Reference: PI21/00462 Duration: 01/01/2022 - 30/06/2026
IP: Maria Jose Soler Romeo Collaborators: Sara Nuñez Delgado, Marina Lopez Martinez, Jordi Vilardell Vila, Irene Martinez Diaz, Sheila Bermejo Garcia, Vicent Muñoz Vaño, Carmen Llorens Cebriá, M Antonieta Azancot Rivero, Enzamaría Fidilio Meli, ROL DE LA APELINA EN LA ENFERMEDAD RENAL DIABÉTICA: DEL RATÓN AL HUMANO Funding agency: Instituto de Salud Carlos III Funding: 190000 Reference: PI24/01510 Duration: 01/01/2025 - 31/12/2027
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The document provides recommendations for identifying people who are candidates for these treatments and for guiding their implementation and follow-up in clinical practice.
The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.
